Related Experiment Video
Updated: Jun 12, 2026
Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
Residual platelet reactivity: predicting short- and long-term clinical outcome in patients undergoing percutaneous
Fabio Mangiacapra1, Emanuele Barbato
1Cardiovascular Center, OLV Hospital, Moorselbaan n. 164, B-9300 Aalst, Belgium.
Insights
Monitoring platelet inhibition is crucial after percutaneous coronary intervention. Patients with high residual platelet reactivity face increased ischemic event risk, suggesting tailored antithrombotic strategies may improve outcomes.
Area of Science:
- Cardiology
- Pharmacology
- Thrombosis
Background:
- Dual antiplatelet therapy (aspirin and thienopyridine) is standard after percutaneous coronary intervention (PCI) to prevent thrombotic events.
- Significant inter-individual variability in response to antiplatelet drugs necessitates monitoring.
- Residual platelet reactivity impacts clinical outcomes in PCI patients.
Purpose of the Study:
- To review methodologies for monitoring antiplatelet therapy response.
- To highlight the clinical implications of residual platelet reactivity post-PCI.
- To discuss the potential benefits of personalized antithrombotic strategies.
Main Methods:
- Review of studies utilizing various platelet function monitoring methodologies.
- Assessment of different pathways of platelet activation and aggregation.
- Correlation of residual platelet reactivity with ischemic event rates.
Main Results:
- Patients with high residual platelet reactivity show increased risk of short- and long-term ischemic events.
- Platelet function tests can identify patients at higher risk.
- Variability in platelet response is influenced by multiple factors.
Conclusions:
- Monitoring platelet function is essential in PCI patients.
- High residual platelet reactivity identifies patients who may benefit from intensified antithrombotic therapy.
- Personalized antithrombotic strategies guided by platelet function testing can reduce ischemic complications.
Abstract:
Adequate platelet inhibition is mandatory in patients undergoing percutaneous coronary intervention in order to prevent recurrent thrombotic events. Dual antiplatelet therapy with aspirin and thienopyridine (e.g., clopidogrel) is the treatment of choice in this setting, providing clear clinical benefit in most of the patients. However, a wide interindividual variability exists in the response to antiplatelet drugs and several factors may contribute to determine fluctuation in platelet reactivity, even within the individual patient. Several methodologies and devices have been developed to monitor individual response to antiplatelet treatment, assessing different pathways of platelet activation and aggregation. Studies performed with the use of these methodologies have clearly demonstrated that patients with high post-treatment residual platelet reactivity present a higher risk of ischemic events both at short (during or soon after percutaneous coronary intervention) and long term. In these patients, more aggressive antithrombotic strategies, based on the results of platelet function tests, may be beneficial in order to reduce ischemic complications after percutaneous coronary intervention.
Related Concept Videos
01:22Formation of the Platelet Plug
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:16Clot Retraction and Fibrinolysis
01:27Peripheral Artery Disease III: Interprofessional Care